Loading company…
Teclison develops therapies for cancer, including a candidate targeting tumors with liver metastasis.
Teclison is a clinical-stage biotechnology company developing cancer treatments. Its lead candidate, TEC-001, is being evaluated as a monotherapy and with immune checkpoint inhibitors for solid cancers, including liver, colorectal, and lung cancers. Based in Montclair, US, the company raised USD 5.9 million in February 2022, led by W.T.T. Investment with Nestor Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in